HER2-Low Unresectable/Metastatic Breast Cancer Complicated With Visceral Crisis

Clinical trial pipeline · Data from ClinicalTrials.gov

See which HER2-Low Unresectable/Metastatic Breast Cancer Complicated With Visceral Crisis trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingPhase 2

NCT07203729

The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients…

The goal of this clinical trial is to learn if Trastuzumab Rezetecan (SHR-A1811) is safe and tolerable for patients with HER2-Low unresectable/metastatic breast…

China184 participantsStarted 2026-03-01

Treatment: Trastuzumab Rezetecan, Chemotherapy of Physician's Choice

HER2-Low Unresectable/Metastatic Breast Cancer Complicated With Visceral Crisis

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients…

All recent trials (1 shown)

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients…

All recent trials (1 shown)